We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+75.12%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$96.8M
AUM Growth
+$25.1M
Cap. Flow
-$7.48M
Cap. Flow %
-7.73%
Top 10 Hldgs %
75.97%
Holding
36
New
8
Increased
5
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$3.14M
2
CMPX icon
Compass Therapeutics
CMPX
+$2.65M
3
OCUL icon
Ocular Therapeutix
OCUL
+$1.8M
4
KRYS icon
Krystal Biotech
KRYS
+$1.58M
5
DRUG
Bright Minds Biosciences
DRUG
+$1.41M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$5.31M
2
TRVI icon
Trevi Therapeutics
TRVI
+$2.7M
3
CDTX
Cidara Therapeutics
CDTX
+$2.43M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.38M
5
BBOT
BridgeBio Oncology
BBOT
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.28B
$13.6M 14.08%
1,165,206
+150,266
+15% +$1.8M
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
$13.6M 14.01%
141,529
-38,040
-21% -$2.43M
TRML
3
DELISTED
Tourmaline Bio
TRML
$12.8M 13.27%
268,451
-15,231
-5% -$422K
WHWK
4
Whitehawk Therapeutics
WHWK
$263M
$6.48M 6.7%
3,410,402
– –
INSM icon
5
Insmed
INSM
$25.9B
$5.56M 5.74%
38,592
+1,522
+4% +$186K
DRUG
6
Bright Minds Biosciences
DRUG
$714M
$5.15M 5.32%
84,875
+36,401
+75% +$1.41M
ARGX icon
7
argenx
ARGX
$64B
$4.7M 4.86%
6,379
-323
-5% -$213K
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$3.87B
$4.53M 4.68%
+333,258
New +$3.14M
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$3.78M 3.9%
502,797
+38,933
+8% +$249K
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.9B
$3.31M 3.42%
25,114
-1,169
-4% -$140K
CMPX icon
11
Compass Therapeutics
CMPX
$432M
$2.94M 3.04%
+840,090
New +$2.65M
PRAX icon
12
Praxis Precision Medicines
PRAX
$9.63B
$2.64M 2.72%
49,751
-24,336
-33% -$1.18M
SRZN icon
13
Surrozen
SRZN
$264M
$2.3M 2.38%
178,415
+8,415
+5% +$88.2K
ASND icon
14
Ascendis Pharma A/S
ASND
$16.3B
$1.95M 2.01%
9,792
-12,784
-57% -$2.38M
KRYS icon
15
Krystal Biotech
KRYS
$10.4B
$1.87M 1.93%
+10,573
New +$1.58M
OCS icon
16
Oculis Holding
OCS
$678M
$1.79M 1.85%
101,777
-4,941
-5% -$87.6K
TSHA icon
17
Taysha Gene Therapies
TSHA
$1.88B
$1.49M 1.54%
454,827
-30,842
-6% -$87.3K
COGT icon
18
Cogent Biosciences
COGT
$6.02B
$1.48M 1.53%
+102,907
New +$1.22M
ZYME icon
19
Zymeworks
ZYME
$2.02B
$1.37M 1.41%
80,143
-3,512
-4% -$50.3K
VSTM icon
20
Verastem
VSTM
$654M
$1.27M 1.31%
143,446
-6,968
-5% -$51.9K
DNTH icon
21
Dianthus Therapeutics
DNTH
$5.92B
$984K 1.02%
+25,000
New +$639K
UTHR icon
22
United Therapeutics
UTHR
$22.1B
$963K 0.99%
+2,296
New +$772K
INBX icon
23
Inhibrx
INBX
$1.82B
$552K 0.57%
+16,377
New +$403K
FULC icon
24
Fulcrum Therapeutics
FULC
$294M
$526K 0.54%
57,141
-2,509
-4% -$18.2K
LBRX
25
LB Pharmaceuticals
LBRX
$1.54B
$474K 0.49%
+30,000
New +$476K
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Acuta Capital Partners held 36 positions worth $96.8M, up 35% from $71.6M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Acuta Capital Partners withdrew a net $7.48M in Q3 2025, closing 8 positions and reducing 13 holdings. Its most notable exit was Soleno Therapeutics, an estimated $5.31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Acuta Capital Partners opened a new position in Amylyx Pharmaceuticals worth $4.53M.

  • Acuta Capital Partners's largest Q3 2025 buy was Amylyx Pharmaceuticals: 333,258 shares worth $4.53M.
  • Acuta Capital Partners added most to Ocular Therapeutix in Q3 2025, an estimated $1.8M increase.
  • Acuta Capital Partners's biggest Q3 2025 reduction was Cidara Therapeutics, cutting an estimated $2.43M.
  • Acuta Capital Partners fully exited Soleno Therapeutics in Q3 2025, selling an estimated $5.31M.
  • Acuta Capital Partners's ten largest holdings make up 76% of its $96.8M portfolio in Q3 2025.
  • Acuta Capital Partners opened 8 new positions and closed 8 in Q3 2025.
  • Acuta Capital Partners's portfolio value rose 35% quarter-over-quarter to $96.8M.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.